Allogene Therapeutics (ALLO) Net Equity Issued and Repurchased (2018 - 2026)

Allogene Therapeutics (ALLO) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $20.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Equity Issued and Repurchased rose 106.64% year-over-year to $20.7 million; the trailing twelve-month figure through Mar 2026 stood at $10.7 million (down 36.38% YoY), and the FY2024 full-year result was $6.8 million, down 92.58% from the prior year.
• Net Equity Issued and Repurchased grew to $20.7 million in Q1 2026, from -$11.5 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $105.3 million in Q2 2024 to a low of -$104.3 million in Q3 2024.
• A 4-year average of $14.8 million and a median of $7.9 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased plunged 98.56% in 2025 and surged 106.64% in 2026, its largest moves.
• Tracing ALLO's Net Equity Issued and Repurchased over 4 years: stood at $91.1 million in 2023, then sank by 93.7% to $5.7 million in 2024, then sank by 300.52% to -$11.5 million in 2025, then soared by 279.47% to $20.7 million in 2026.
• Business Quant data shows ALLO's Net Equity Issued and Repurchased at $20.7 million in Q1 2026, -$11.5 million in Q3 2025, and $1.5 million in Q2 2025.